[go: up one dir, main page]

KR930017919A - Cd40 b-세포 항원에 대한 역-수용체 및 이에대한 리간드 - Google Patents

Cd40 b-세포 항원에 대한 역-수용체 및 이에대한 리간드 Download PDF

Info

Publication number
KR930017919A
KR930017919A KR1019930002045A KR930002045A KR930017919A KR 930017919 A KR930017919 A KR 930017919A KR 1019930002045 A KR1019930002045 A KR 1019930002045A KR 930002045 A KR930002045 A KR 930002045A KR 930017919 A KR930017919 A KR 930017919A
Authority
KR
South Korea
Prior art keywords
ligand
molecule
cd40cr
soluble ligand
soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019930002045A
Other languages
English (en)
Other versions
KR100301146B1 (ko
Inventor
에이. 아루포 알레쟌드로
에이. 레드베터 제프레이
노엘 란돌프
스타멘코빅 이반
Original Assignee
도미닉 엠. 메자펠
브리스톨-마이어스 스퀴브 캄파니
원본미기재
트러스티스 오브 다르트마우스 컬리지
더 제네랄 호스피탈 코포레이션 디/비/에이 매사츄세츠 제네랄 호스피탈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25270498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR930017919(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 도미닉 엠. 메자펠, 브리스톨-마이어스 스퀴브 캄파니, 원본미기재, 트러스티스 오브 다르트마우스 컬리지, 더 제네랄 호스피탈 코포레이션 디/비/에이 매사츄세츠 제네랄 호스피탈 filed Critical 도미닉 엠. 메자펠
Publication of KR930017919A publication Critical patent/KR930017919A/ko
Application granted granted Critical
Publication of KR100301146B1 publication Critical patent/KR100301146B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

본 발명은, CD40 B-세포 항원에 대한 역-수용체(CD40CR), 및 단백질의 적어도 일부를 함유한 융합분자를 포함한, CD40CR에 대한 가용성 리간드에 관한 것이다. 본 발명은 가용성 CD40면역글로블린 융합 단백질이 조력T-세포막상의 신규한 39kD 단백질 수용체와 결합함으로써 조력 T-세포 중재된B-세포 활성화를 억제 시킬 수 있었다는 발견을, 적어도 부분으로, 기초로한다. 본 발명은 실질적으로 정제된 CD40CR 수용체 ; CD40단백질의 적어도 일부를 함유한 융합분자 뿐만 아니라 항체를 포함한, CD40CR의 가용성 리간드; 및 알레르기 또는 자가면역질환의 치료에 특히 유용할 수 있는 B-세포 활성화를 조절하는 방법을 제공한다.

Description

CD40 B-세포 항원에 대한 역-수용체 및 이에대한 리간드
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 PMAct에 의한 B-세포 RNA합성의 유도에 미치는 모노클로날 항체 및 CD40-1g의 영향력을 보여주는 그래프다. 제2도는 CD40-1g가 B-세포와 분화 및 증식을 억제하였음을 보여주는 그래프이다. 제3도는 정지상태가 아닌 활성화된 Th상에 발현된 분자에 대한 CD40-1g의 검색도이다.

Claims (41)

  1. 실질적으로 정제된 CD40CR 수용액.
  2. 제1항에 있어서, 약 39킬로달톤의 분자량을 갖는 실질적으로 정제된 수용체.
  3. 제1항에 있어서, CD40-1g과 결합하는 실질적으로 정제된 수용체.
  4. 제1항에 있어서, 모노클로날항체 MR1과 결합하는 실질적으로 정제된 수용체.
  5. CD40단백질의 적어도 일부를 함유하는, CD40CR에 대한 가용성 리간드.
  6. 제5항에 있어서, 막전이 도메인인 결실된 CD40단백질의 일부를 함유하는 가용성 리간드.
  7. 제5항 또는 제6항에 있어서, 면역글로블린 분자의 적어도 일부를 추가로 함유하는 가용성 리간드.
  8. 제5항에 있어서, CD40-1g인 가용성 리간드.
  9. 면역글로블린 분자의 적어도 일부를 함유하는, CD40CR에 대한 가용성 리간드.
  10. 제9항에 있어서, 면역글로블린 분자가 CD40과 CD40CR과의 결합을 경쟁적으로 억제시킬 수 있는 가용성 리간드.
  11. 제9항에 있어서, 면역글로블린 분자가 모노클로날항체와 이의 표적항원과의 결합을 경쟁적으로 억제시킬 수 있는 가용성 리간드.
  12. 제9항, 10항 또는 11항에 있어서, 증식억제제인 제2분자를 추가로 함유하는 가용성 리간드.
  13. 제9항, 10항 또는 11항에 있어서, 알킬화제인 제2분자를 추가로 함유하는 가용성 리간드.
  14. 제9항, 10항 또는 11항에 있어서, 항대사물질인 제2분자를 추가로 함유하는 가용성 리간드.
  15. 제9항, 10항 또는 11항에 있어서, 항생물질인 제2분자를 추가로 함유하는 가용성 리간드.
  16. 제9항, 10항 또는 11항에 있어서, 빈카알카로이드인 제2분자를 추가로 함유하는 가용성 리간드.
  17. 제9항, 10항 또는 11항에 있어서, 효소인 제2분자를 추가로 함유하는 가용성 리간드.
  18. 제9항, 10항 또는 11항에 있어서, 백금배위착염인 제2분자를 추가로 함유하는 가용성 리간드.
  19. 제9항, 10항 또는 11항에 있어서, 방사성동위원소인 제2분자를 추가로 함유하는 가용성 리간드.
  20. 제9항, 10항 또는 11항에 있어서, 형광화합물인 제2분자를 추가로 함유하는 가용성 리간드.
  21. 모노클로날항체 MRI 또는 이의 단편.
  22. B-세포와 조력T세포의 혼합물을 CD40CR과 결합하는 유효농도의 리간드에 노출시켜, B-세포 활성화를 억제하는 방법.
  23. 제22항에 있어서, 리간드가 CD40단백질의 적어도 일부를 함유하는 방법.
  24. 제22항에 있어서, 리간드가 막전이 도메인이 결실된 CD40 단백질의 일부를 함유하는 방법.
  25. 제23항 또는 24항에 있어서, 리간드가 면역글로블린 분자의 적어도 일부를 추가로 함유하는 방법.
  26. 제22항에 있어서, 리간드가 CD40-1g인 방법.
  27. 제22항에 있어서, 리간드가 면역글로블린 분자의 적어도 일부를 함유하는 방법.
  28. 제27항에 있어서, 면역글로블린 분자가 CD40과 CD40CR과의 결합을 경쟁적으로 억제시킬 수 있는 방법.
  29. 제27항에 있어서, 면역글로블린 분자가 모노클로날항체 MRI과 이의 표적항원과의 결합을 경쟁적으로 억제시킬 수 있는 방법.
  30. B-세포 활성화와 연관된 질환을 앓고 있는 대상자에게 CD40CR과 결합하는 치료량의 리간드를 투여하여, 그 대상자를 치료하는 방법.
  31. 제30항에 있어서, 질환이 알레르기인 방법.
  32. 제30항에 있어서, 질환이 자가면역질환인 방법.
  33. 제30항에 있어서, 리간드가 CD40단백질의 적어도 일부를 함유하는 방법.
  34. 제30항에 있어서, 막전이 도메인인 결실된 CD40단백질의 일부를 함유하는 방법.
  35. 제33항 또는 제34항에 있어서, 리간드가 면역글로블린 분자의 적어도 일부를 추가로 함유하는 방법.
  36. 제30항에 있어서, 리간드가 CD40-1g인 방법.
  37. 제30항에 있어서, 리간드가 면역글로블린 분자의 적어도 일부를 함유하는 방법.
  38. 제37항에 있어서, 면역글로블린 분자가 CD40과 CD40CR과의 결합을 경쟁적으로 억제시킬 수 있는 방법.
  39. 제37항에 있어서, 면역글로블린 분자가 모노클로날항체 MRI과 이의 표적항원과의 결합을 경쟁적으로 억제시킬 수 있는 방법.
  40. 적합한 약제학적 담체중에 CD40-1g을 함유하는 약제조성물.
  41. 적합한 약제학적 담체중에 모노클로날항체 MRI또는 이의 단편을 함유한 약제조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930002045A 1992-02-14 1993-02-13 Cd4ob-세포항원에대한역-수용체및이에대한리간드 Expired - Fee Related KR100301146B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83579992A 1992-02-14 1992-02-14
US07/835,799 1992-02-14

Publications (2)

Publication Number Publication Date
KR930017919A true KR930017919A (ko) 1993-09-20
KR100301146B1 KR100301146B1 (ko) 2001-10-22

Family

ID=25270498

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930002045A Expired - Fee Related KR100301146B1 (ko) 1992-02-14 1993-02-13 Cd4ob-세포항원에대한역-수용체및이에대한리간드

Country Status (16)

Country Link
US (2) US6376459B1 (ko)
EP (2) EP1489099A3 (ko)
JP (2) JP4148537B2 (ko)
KR (1) KR100301146B1 (ko)
AT (1) ATE273998T1 (ko)
AU (2) AU3298893A (ko)
CA (1) CA2089229C (ko)
DE (1) DE69333591T2 (ko)
DK (1) DK0555880T3 (ko)
ES (1) ES2225820T3 (ko)
FI (1) FI117508B (ko)
IL (1) IL104684A0 (ko)
NO (1) NO316024B1 (ko)
NZ (1) NZ245898A (ko)
PT (1) PT555880E (ko)
ZA (1) ZA931013B (ko)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0897983B1 (en) * 1991-10-25 2003-05-07 Immunex Corporation Antibody against CD40-L
US5981724A (en) * 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5961974A (en) 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US7070777B1 (en) * 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
IL104684A0 (en) 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
WO1994004570A1 (en) * 1992-08-21 1994-03-03 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
EP0721346B1 (en) * 1993-09-02 1998-06-10 Trustees of Dartmouth College Methods for inducing antigen-specific t cell tolerance
ZA946765B (en) 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
IL110852A (en) * 1993-09-02 1999-05-09 Dartmouth College Methods of prolonged suppression of humoral activity
AU1059095A (en) * 1993-11-24 1995-06-13 Australian National University, The Treatment of viral disease with cd40l peptide
US5683693A (en) 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
CA2188165C (en) 1994-04-28 2007-08-28 Marilyn Kehry Methods for proliferating and differentiating b cells, and uses thereof
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5652224A (en) * 1995-02-24 1997-07-29 The Trustees Of The University Of Pennsylvania Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
US6251957B1 (en) 1995-02-24 2001-06-26 Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant virus
US6372208B1 (en) 1999-09-28 2002-04-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant virus
AU2556195A (en) 1995-03-13 1996-10-02 Regents Of The University Of Michigan, The CD40 binding compositions and methods of using same
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US7427492B1 (en) 1995-06-05 2008-09-23 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor receptor-like2
US7175847B1 (en) 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US7153508B2 (en) 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
JPH11508262A (ja) * 1995-06-22 1999-07-21 バイオジェン，インコーポレイテッド Ｃｄ４０リガンドのフラグメントの結晶およびその使用
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US5916560A (en) * 1996-03-20 1999-06-29 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways and compositions for use therewith
EE9900010A (et) * 1996-07-08 1999-06-15 The Trustees Of Columbia University In The City Of New York T-BAM (CD40L) tehnoloogia terapeutilised rakendused silelihasrakkudega seotud haiguste ravimiseks
DE69803392D1 (de) 1997-06-20 2002-02-28 Tanox Pharma B V Anti-cd40l immunotoxine zur behandlung von krankheiten
CA2223225A1 (en) * 1997-11-28 1999-05-28 Canadian Red Cross Society Method for inhibiting in vivo immune response
EP1067954A4 (en) * 1998-04-03 2004-08-18 Dartmouth College USE OF ANTI-GP39 ANTIBODIES FOR TREATING AND / OR REGRESSING LUPUS AND RELATED KIDNEY DISEASE
IL130989A0 (en) * 1999-07-20 2001-01-28 Compugen Ltd Variants of alternative splicing
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
CA2424749A1 (en) 2000-10-02 2002-04-11 Chiron Corporation Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
EP1485480A2 (en) * 2002-02-22 2004-12-15 Compugen Ltd. Cd40 splice variants, method of detection thereof, compositions comprising said variant(s) or nucleic acid encoding the same and use thereof
US20080199471A1 (en) * 2002-03-01 2008-08-21 Bernett Matthew J Optimized cd40 antibodies and methods of using the same
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
EP2270049A3 (en) 2002-04-12 2011-03-09 Medimmune, Inc. Recombinant anti-interleukin-9-antibody
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
CA2521826C (en) 2003-04-11 2013-08-06 Jennifer L. Reed Recombinant il-9 antibodies and uses thereof
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
CN1897959A (zh) 2003-09-29 2007-01-17 沃伦药品公司 用于治疗和预防脓毒病和粘连形成的组织保护细胞因子
US20050136055A1 (en) * 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
US7351739B2 (en) 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
JP5102028B2 (ja) 2004-07-26 2012-12-19 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗ｃｄ１５４抗体
WO2006047639A2 (en) 2004-10-27 2006-05-04 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
US20060148080A1 (en) * 2004-12-30 2006-07-06 Paul Diamond Methods for supporting and producing human cells and tissues in non-human mammal hosts
DK1912675T3 (en) * 2005-07-25 2014-03-24 Emergent Product Dev Seattle B-cell reduction using specific and cd37-cd20-specific binding molecules
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
US8697846B2 (en) * 2007-08-15 2014-04-15 Emory University Methods of making monoclonal antibodies using fusion-peptide epitope adoptive transfer (F-PEAT) technology
ATE513856T1 (de) 2008-04-11 2011-07-15 Emergent Product Dev Seattle Cd37-immuntherapeutikum und kombination mit bifunktionellem chemotherapeutikum davon
US9598491B2 (en) 2008-11-28 2017-03-21 Emory University Methods for the treatment of infections and tumors
CN106977604A (zh) 2011-04-21 2017-07-25 百时美施贵宝公司 拮抗cd40之抗体多肽
WO2015134988A1 (en) 2014-03-07 2015-09-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
EA201890613A1 (ru) 2015-09-21 2018-10-31 Аптево Рисёрч Энд Девелопмент Ллс Полипептиды, связывающие cd3
WO2018162563A1 (en) * 2017-03-07 2018-09-13 Universität Basel Mr1 restricted t cell receptors for cancer immunotherapy
KR20200010294A (ko) 2017-05-24 2020-01-30 에이엘에스 테라피 디벨럽먼트 인스티튜트 치료용 항-cd40 리간드 항체
WO2018222506A1 (en) * 2017-05-27 2018-12-06 Immune-Onc Therapeutics, Inc. Modulation of immunoglobulin-a-positive cells
WO2024211211A1 (en) 2023-04-03 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods of improving transplant survival using il-2 receptor gamma chain antibodies

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5247069A (en) * 1986-06-13 1993-09-21 Oncogen Ligands and methods for augmenting B-cell proliferation
DE3815472A1 (de) * 1988-05-06 1989-11-16 Centre Regional De Transfusion Monoklonaler antikoerper und seine verwendung
JP3722375B2 (ja) * 1991-06-27 2005-11-30 ブリストル−マイヤーズ スクイブ カンパニー Ｃｔｌａ４レセプター、それを含有する融合タンパク質およびそれらの使用
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
IL104684A0 (en) 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5833987A (en) 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
WO1998030240A1 (en) 1997-01-10 1998-07-16 Biogen, Inc. Treatment of lupus nephritis with anti-cd40l compounds
AU5623398A (en) 1997-03-07 1998-09-22 Biogen, Inc. Methods of therapeutic administration of anti-cd40l compounds
AU8266798A (en) 1997-06-27 1999-01-19 Biogen, Inc. Cd154 blockade therapy for autoimmune diseases

Also Published As

Publication number Publication date
MX9300768A (es) 1997-09-30
EP1489099A3 (en) 2008-02-20
AU7198096A (en) 1997-02-06
CA2089229A1 (en) 1993-08-15
NO316024B1 (no) 2003-12-01
NO930521D0 (no) 1993-02-12
ZA931013B (en) 1993-09-20
PT555880E (pt) 2004-12-31
US20060008460A1 (en) 2006-01-12
CA2089229C (en) 2010-04-13
JP4148537B2 (ja) 2008-09-10
ATE273998T1 (de) 2004-09-15
AU701306B2 (en) 1999-01-28
EP1489099A2 (en) 2004-12-22
JPH06220096A (ja) 1994-08-09
FI117508B (fi) 2006-11-15
NO930521L (no) 1993-08-16
FI930605L (fi) 1993-08-15
JP2004115527A (ja) 2004-04-15
AU3298893A (en) 1993-08-19
DE69333591D1 (de) 2004-09-23
ES2225820T3 (es) 2005-03-16
US7445781B2 (en) 2008-11-04
EP0555880B1 (en) 2004-08-18
FI930605A0 (fi) 1993-02-11
DK0555880T3 (da) 2004-12-06
KR100301146B1 (ko) 2001-10-22
NZ245898A (en) 1995-04-27
IL104684A0 (en) 1993-06-10
JP3984944B2 (ja) 2007-10-03
EP0555880A3 (en) 1994-05-11
DE69333591T2 (de) 2005-09-01
EP0555880A2 (en) 1993-08-18
US6376459B1 (en) 2002-04-23

Similar Documents

Publication Publication Date Title
KR930017919A (ko) Cd40 b-세포 항원에 대한 역-수용체 및 이에대한 리간드
Cunningham et al. Molecular topography of the neural cell adhesion molecule N-CAM: surface orientation and location of sialic acid-rich and binding regions.
Taunton et al. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p
Tenner et al. Analysis of receptor-mediated C1q binding to human peripheral blood mononuclear cells.
Sachs et al. An immunologic approach to the conformational equilibria of polypeptides
Kulczycki Jr et al. The interaction of IgE with rat basophilic leukemia cells: I. evidence for specific binding of IgE
RU2236257C1 (ru) Синтетический иммуноген для терапии и профилактики злоупотреблений наркотическими и психоактивными веществами
Hohlfeld et al. Myasthenia gravis: stimulation of antireceptor autoantibodies by autoreactive T cell lines
Würzner et al. Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies
Wilson et al. Monoclonal antibodies to the 140,000 mol wt glycoprotein of B lymphocyte membranes (CR2 receptor) initiates proliferation of B cells in vitro
Isenman et al. The interaction of C5 with C3b in free solution: a sufficient condition for cleavage by a fluid phase C3/C5 convertase.
US4772685A (en) Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
Tedesco et al. Two types of dysfunctional eighth component of complement (C8) molecules in C8 deficiency in man. Reconstitution of normal C8 from the mixture of two abnormal C8 molecules.
JPS61501912A (ja) 合成ポリペプチドにより誘発されたヒトインタ−ロイキン−２に対する抗体
Burnett et al. Allergic encephalomyelitis: Oxidation and cleavage of the single tryptophan residue of the A1 protein from bovine and human myelin
Delpinoi et al. Cell surface localization of the 78 kD glucose regulated protein (GRP 78) induced by thapsigargin
Suemura et al. Potentiation of IgE response in vitro by T cells from rats infected with Nippostrongylus brasiliensis
Kleppel et al. Immunochemical studies of the Alport antigen
Vidal et al. Alternative mechanism of protein A-immunoglobulin interaction the VH-associated reactivity of a monoclonal human IgM.
Vivanco et al. The covalent interaction of C3 with IgG immune complexes
WO1991002005A1 (en) Natural human anti-gamma interferon antibodies detected and purified by synthetic peptides
Basset-Seguin et al. C3d, g is present in normal human epidermal basement membrane.
Kosaka et al. Hyperviscosity syndrome associated with an idiopathic monoclonal IgA-rheumatoid factor
Honda et al. Vaccination with an immunodominant peptide of bovine type II collagen induces an anti‐TCR response, and modulates the onset and severity of collagen‐induced arthritis
Gottlieb et al. A cross-reaction between β2-microglobulin and κ-light chains

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19930213

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19980217

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19930213

Comment text: Patent Application

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19991126

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20000324

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 19991126

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20000424

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20000324

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20010331

Appeal identifier: 2000101000875

Request date: 20000424

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20000424

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20000424

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 19980421

Patent event code: PB09011R02I

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20000629

Patent event code: PE09021S01D

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20010331

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20000530

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20010622

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20010622

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20040609

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20050614

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20060612

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20070608

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20080530

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20090609

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20100610

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20100610

Start annual number: 10

End annual number: 10

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Termination category: Default of registration fee

Termination date: 20120509